Lung Cancer
A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Details
ClinicalTrials.gov ID:
NCT07005102
Diagnosis Type:
NA
USOR Number:
- Address
,
P: